Black Diamond Therapeutics vs Compugen
Compugen reported revenue of $73 million in fiscal 2025, about the same as Black Diamond Therapeutics' $70 million in fiscal 2025. Black Diamond Therapeutics had an operating margin of 17.9%, against 43.0% at Compugen.
Side by side
| Black Diamond Therapeutics | Compugen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $70M | $73M |
| Revenue growth | — | 161.1% |
| Revenue growth a year, last 5 years | — | 105.2% |
| Gross margin | — | 87.3% |
| Operating margin | 17.9% | 43.0% |
| Net margin | 31.9% | 48.6% |
| Free cash flow | — | $31M |
| Free cash flow margin | — | 43.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.6% | 4.8% |
| Last close | $1.39 | $1.88 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $118,302 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Black Diamond TherapeuticsCompugen
Operating margin
Percent of revenue
Black Diamond TherapeuticsCompugen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Black Diamond TherapeuticsCompugen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Black Diamond Therapeutics and Compugen pages.